25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Silverback Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Silverback Therapeutics Inc together

I guess you are interested in Silverback Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Silverback Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Silverback Therapeutics Inc

I send you an email if I find something interesting about Silverback Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Silverback Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Silverback Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.22
Expected worth in 1 year
$1.88
How sure are you?
18.2%

+ What do you gain per year?

Total Gains per Share
$-0.34
Return On Investment
-2.3%

For what price can you sell your share?

Current Price per Share
$15.26
Expected price per share
$9.31 - $17.08
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Silverback Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$15.26

2.2. Growth of Silverback Therapeutics Inc (5 min.)




Is Silverback Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$215.2m$262.4m-$35.6m-15.7%

How much money is Silverback Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$11.2m-$12.3m$1.1m10.6%
Net Profit Margin5,347.5%-58,581.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Silverback Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Silverback Therapeutics Inc?

Welcome investor! Silverback Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Silverback Therapeutics Inc.

First you should know what it really means to hold a share of Silverback Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Silverback Therapeutics Inc is $15.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Silverback Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Silverback Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.22. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $0.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Silverback Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.13-0.8%-0.12-0.8%-0.06-0.4%-0.08-0.5%-0.08-0.5%
Usd Book Value Change Per Share-0.09-0.6%-0.09-0.6%0.754.9%0.201.3%0.201.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-0.6%-0.09-0.6%0.754.9%0.201.3%0.201.3%
Usd Price Per Share8.51-7.00-6.76-6.31-6.31-
Price to Earnings Ratio-16.48--16.31--4.87--12.88--12.88-
Price-to-Total Gains Ratio-95.63--88.33-9.65--36.76--36.76-
Price to Book Ratio3.83-3.03-2.49--1.71--1.71-
Price-to-Total Gains Ratio-95.63--88.33-9.65--36.76--36.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.26
Number of shares65
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.090.20
Usd Total Gains Per Share-0.090.20
Gains per Quarter (65 shares)-5.5813.12
Gains per Year (65 shares)-22.3452.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-22-3205242
20-45-54010594
30-67-760157146
40-89-980210198
50-112-1200262250
60-134-1420315302
70-156-1640367354
80-179-1860420406
90-201-2080472458
100-223-2300525510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.010.00.09.1%1.010.00.09.1%1.010.00.09.1%1.010.00.09.1%
Book Value Change Per Share0.04.00.00.0%2.08.01.018.2%2.08.01.018.2%2.08.01.018.2%2.08.01.018.2%
Dividend per Share0.00.04.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%
Total Gains per Share0.04.00.00.0%2.08.01.018.2%2.08.01.018.2%2.08.01.018.2%2.08.01.018.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Silverback Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.089-0.086-3%0.755-112%0.202-144%0.202-144%
Book Value Per Share--2.2202.339-5%2.707-18%1.735+28%1.735+28%
Current Ratio--32.77953.082-38%42.855-24%36.667-11%36.667-11%
Debt To Asset Ratio--0.0300.026+18%0.0300%0.473-94%0.473-94%
Debt To Equity Ratio--0.0310.026+18%0.031-1%0.021+48%0.021+48%
Dividend Per Share----0%-0%-0%-0%
Eps---0.129-0.116-10%-0.059-54%-0.082-37%-0.082-37%
Free Cash Flow Per Share---0.075-0.114+51%-0.144+90%-0.111+48%-0.111+48%
Free Cash Flow To Equity Per Share---0.070-0.105+50%0.363-119%0.100-170%0.100-170%
Gross Profit Margin--0.9990.9990%1.0000%1.0000%1.0000%
Market Cap1479328816.000+44%824973016.000678348846.000+22%654840508.000+26%611789624.727+35%611789624.727+35%
Net Profit Margin---25.03253.475-147%-585.811+2240%-195.777+682%-195.777+682%
Operating Margin---30.68077.547-140%-763.993+2390%-251.826+721%-251.826+721%
Operating Ratio--31.680-77.297+344%1027.155-97%349.397-91%349.397-91%
Pb Ratio6.873+44%3.8333.026+27%2.494+54%-1.708+145%-1.708+145%
Pe Ratio-29.549-79%-16.478-16.311-1%-4.867-70%-12.879-22%-12.879-22%
Price Per Share15.260+44%8.5106.998+22%6.755+26%6.311+35%6.311+35%
Price To Free Cash Flow Ratio-50.544-79%-28.187-19.868-30%-13.663-52%-17.608-38%-17.608-38%
Price To Total Gains Ratio-171.477-79%-95.627-88.332-8%9.647-1091%-36.759-62%-36.759-62%
Quick Ratio--59.69291.198-35%57.115+5%55.622+7%55.622+7%
Return On Assets---0.056-0.048-15%-0.046-18%-0.065+16%-0.065+16%
Return On Equity---0.058-0.049-15%-0.048-18%-0.035-39%-0.035-39%
Total Gains Per Share---0.089-0.086-3%0.755-112%0.202-144%0.202-144%
Usd Book Value--215241000.000226788250.000-5%262416750.000-18%168204545.455+28%168204545.455+28%
Usd Book Value Change Per Share---0.089-0.086-3%0.755-112%0.202-144%0.202-144%
Usd Book Value Per Share--2.2202.339-5%2.707-18%1.735+28%1.735+28%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.129-0.116-10%-0.059-54%-0.082-37%-0.082-37%
Usd Free Cash Flow---7317000.000-11057500.000+51%-13914000.000+90%-10797681.818+48%-10797681.818+48%
Usd Free Cash Flow Per Share---0.075-0.114+51%-0.144+90%-0.111+48%-0.111+48%
Usd Free Cash Flow To Equity Per Share---0.070-0.105+50%0.363-119%0.100-170%0.100-170%
Usd Market Cap1479328816.000+44%824973016.000678348846.000+22%654840508.000+26%611789624.727+35%611789624.727+35%
Usd Price Per Share15.260+44%8.5106.998+22%6.755+26%6.311+35%6.311+35%
Usd Profit---12516000.000-11205750.000-10%-12397750.000-1%-10303727.273-18%-10303727.273-18%
Usd Revenue--500000.000117500.000+326%383750.000+30%284727.273+76%284727.273+76%
Usd Total Gains Per Share---0.089-0.086-3%0.755-112%0.202-144%0.202-144%
 EOD+5 -3MRQTTM+11 -23YOY+15 -195Y+18 -1610Y+18 -16

3.3 Fundamental Score

Let's check the fundamental score of Silverback Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-29.549
Price to Book Ratio (EOD)Between0-16.873
Net Profit Margin (MRQ)Greater than0-25.032
Operating Margin (MRQ)Greater than0-30.680
Quick Ratio (MRQ)Greater than159.692
Current Ratio (MRQ)Greater than132.779
Debt to Asset Ratio (MRQ)Less than10.030
Debt to Equity Ratio (MRQ)Less than10.031
Return on Equity (MRQ)Greater than0.15-0.058
Return on Assets (MRQ)Greater than0.05-0.056
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Silverback Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.604
Ma 20Greater thanMa 5015.132
Ma 50Greater thanMa 10014.050
Ma 100Greater thanMa 20012.206
OpenGreater thanClose14.840
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Silverback Therapeutics Inc

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-10-30 19:10:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Silverback Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -2,503.2% means that $-25.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Silverback Therapeutics Inc:

  • The MRQ is -2,503.2%. The company is making a huge loss. -2
  • The TTM is 5,347.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-2,503.2%TTM5,347.5%-7,850.7%
TTM5,347.5%YOY-58,581.1%+63,928.7%
TTM5,347.5%5Y-19,577.7%+24,925.2%
5Y-19,577.7%10Y-19,577.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,503.2%-135.5%-2,367.7%
TTM5,347.5%-202.0%+5,549.5%
YOY-58,581.1%-207.4%-58,373.7%
5Y-19,577.7%-353.2%-19,224.5%
10Y-19,577.7%-466.1%-19,111.6%
4.3.1.2. Return on Assets

Shows how efficient Silverback Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • -5.6% Return on Assets means that Silverback Therapeutics Inc generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Silverback Therapeutics Inc:

  • The MRQ is -5.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.6%TTM-4.8%-0.8%
TTM-4.8%YOY-4.6%-0.2%
TTM-4.8%5Y-6.5%+1.7%
5Y-6.5%10Y-6.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.6%-10.9%+5.3%
TTM-4.8%-11.9%+7.1%
YOY-4.6%-11.2%+6.6%
5Y-6.5%-12.8%+6.3%
10Y-6.5%-14.4%+7.9%
4.3.1.3. Return on Equity

Shows how efficient Silverback Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • -5.8% Return on Equity means Silverback Therapeutics Inc generated $-0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Silverback Therapeutics Inc:

  • The MRQ is -5.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.8%TTM-4.9%-0.9%
TTM-4.9%YOY-4.8%-0.2%
TTM-4.9%5Y-3.5%-1.4%
5Y-3.5%10Y-3.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.8%-13.8%+8.0%
TTM-4.9%-16.1%+11.2%
YOY-4.8%-13.6%+8.8%
5Y-3.5%-18.8%+15.3%
10Y-3.5%-19.0%+15.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Silverback Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Silverback Therapeutics Inc is operating .

  • Measures how much profit Silverback Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -3,068.0% means the company generated $-30.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Silverback Therapeutics Inc:

  • The MRQ is -3,068.0%. The company is operating very inefficient. -2
  • The TTM is 7,754.7%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ-3,068.0%TTM7,754.7%-10,822.7%
TTM7,754.7%YOY-76,399.3%+84,154.0%
TTM7,754.7%5Y-25,182.6%+32,937.3%
5Y-25,182.6%10Y-25,182.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,068.0%-286.0%-2,782.0%
TTM7,754.7%-312.4%+8,067.1%
YOY-76,399.3%-222.0%-76,177.3%
5Y-25,182.6%-386.0%-24,796.6%
10Y-25,182.6%-497.0%-24,685.6%
4.3.2.2. Operating Ratio

Measures how efficient Silverback Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 31.68 means that the operating costs are $31.68 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Silverback Therapeutics Inc:

  • The MRQ is 31.680. The company is inefficient in keeping operating costs low. -1
  • The TTM is -77.297.
Trends
Current periodCompared to+/- 
MRQ31.680TTM-77.297+108.977
TTM-77.297YOY1,027.155-1,104.451
TTM-77.2975Y349.397-426.694
5Y349.39710Y349.3970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.6802.835+28.845
TTM-77.2973.150-80.447
YOY1,027.1553.299+1,023.856
5Y349.3974.839+344.558
10Y349.3976.530+342.867
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Silverback Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Silverback Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 32.78 means the company has $32.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Silverback Therapeutics Inc:

  • The MRQ is 32.779. The company is very able to pay all its short-term debts. +2
  • The TTM is 53.082. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ32.779TTM53.082-20.304
TTM53.082YOY42.855+10.227
TTM53.0825Y36.667+16.416
5Y36.66710Y36.6670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.7793.744+29.035
TTM53.0823.923+49.159
YOY42.8554.713+38.142
5Y36.6675.960+30.707
10Y36.6676.293+30.374
4.4.3.2. Quick Ratio

Measures if Silverback Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 59.69 means the company can pay off $59.69 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Silverback Therapeutics Inc:

  • The MRQ is 59.692. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 91.198. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ59.692TTM91.198-31.507
TTM91.198YOY57.115+34.083
TTM91.1985Y55.622+35.576
5Y55.62210Y55.6220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ59.6923.349+56.343
TTM91.1983.526+87.672
YOY57.1154.682+52.433
5Y55.6225.927+49.695
10Y55.6226.479+49.143
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Silverback Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Silverback Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Silverback Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.03 means that Silverback Therapeutics Inc assets are financed with 3.0% credit (debt) and the remaining percentage (100% - 3.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Silverback Therapeutics Inc:

  • The MRQ is 0.030. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.026. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.030TTM0.026+0.005
TTM0.026YOY0.030-0.005
TTM0.0265Y0.473-0.447
5Y0.47310Y0.4730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0300.338-0.308
TTM0.0260.347-0.321
YOY0.0300.310-0.280
5Y0.4730.366+0.107
10Y0.4730.382+0.091
4.5.4.2. Debt to Equity Ratio

Measures if Silverback Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 3.1% means that company has $0.03 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Silverback Therapeutics Inc:

  • The MRQ is 0.031. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.026. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.031TTM0.026+0.005
TTM0.026YOY0.031-0.005
TTM0.0265Y0.021+0.005
5Y0.02110Y0.0210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0310.393-0.362
TTM0.0260.437-0.411
YOY0.0310.375-0.344
5Y0.0210.450-0.429
10Y0.0210.488-0.467
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Silverback Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Silverback Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -16.48 means the investor is paying $-16.48 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Silverback Therapeutics Inc:

  • The EOD is -29.549. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.478. Based on the earnings, the company is expensive. -2
  • The TTM is -16.311. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-29.549MRQ-16.478-13.070
MRQ-16.478TTM-16.311-0.168
TTM-16.311YOY-4.867-11.444
TTM-16.3115Y-12.879-3.431
5Y-12.87910Y-12.8790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-29.549-2.324-27.225
MRQ-16.478-2.481-13.997
TTM-16.311-2.977-13.334
YOY-4.867-3.429-1.438
5Y-12.879-5.859-7.020
10Y-12.879-6.262-6.617
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Silverback Therapeutics Inc:

  • The EOD is -50.544. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -28.187. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -19.868. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-50.544MRQ-28.187-22.357
MRQ-28.187TTM-19.868-8.319
TTM-19.868YOY-13.663-6.206
TTM-19.8685Y-17.608-2.260
5Y-17.60810Y-17.6080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-50.544-3.155-47.389
MRQ-28.187-3.261-24.926
TTM-19.868-3.507-16.361
YOY-13.663-4.567-9.096
5Y-17.608-8.008-9.600
10Y-17.608-8.700-8.908
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Silverback Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.83 means the investor is paying $3.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Silverback Therapeutics Inc:

  • The EOD is 6.873. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.833. Based on the equity, the company is fair priced.
  • The TTM is 3.026. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD6.873MRQ3.833+3.040
MRQ3.833TTM3.026+0.807
TTM3.026YOY2.494+0.532
TTM3.0265Y-1.708+4.734
5Y-1.70810Y-1.7080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.8731.918+4.955
MRQ3.8331.984+1.849
TTM3.0262.194+0.832
YOY2.4942.392+0.102
5Y-1.7083.563-5.271
10Y-1.7084.200-5.908
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Silverback Therapeutics Inc.

4.8.1. Institutions holding Silverback Therapeutics Inc

Institutions are holding 66.037% of the shares of Silverback Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Deerfield Management Co11.42741.56851107792700
2024-06-30RA Capital Management, LLC11.20361.22251086097700
2024-06-30Orbimed Advisors, LLC9.53241.5528924088700
2024-06-30BlackRock Inc4.21320.00084084339142610053.6483
2024-06-30SR ONE CAPITAL MANAGEMENT, LP4.139510.6918401290300
2024-06-30Vanguard Group Inc3.35350.0005325092736447212.627
2024-06-30Franklin Resources Inc3.04410.0077295096300
2024-06-30K2 PRINCIPAL FUND LP2.53933.8959246167224254110.9295
2024-06-30Nextech Invest AG1.97032.7343191002900
2024-06-30State Street Corp1.91480.0007185622125167115.6848
2024-06-30Geode Capital Management, LLC1.23360.0009119587831920736.4113
2024-06-30FMR Inc1.11960.000610853183960.0365
2024-06-30Perceptive Advisors LLC0.89470.177886731900
2024-06-30Royce & Associates, LP0.66610.05146457008700015.5719
2024-06-30Rubric Capital Management LP0.65940.142663920300
2024-06-30Goldman Sachs Group Inc0.45460.0006440739-21977-4.7496
2024-06-30Amvescap Plc.0.43380.000842057592032.2371
2024-06-30Charles Schwab Investment Management Inc0.42860.00074155307023520.3406
2024-06-30Jacobs Levy Equity Management, Inc.0.37650.01293650278732131.4437
2024-06-30Clarivest Asset Management LLC0.29670.2497287596146405.3635
Total 59.901722.313558069730+2850809+4.9%

4.9.2. Funds holding Silverback Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-08-31Vanguard Total Stock Mkt Idx Inv1.9220.0014186322622190.1192
2024-09-30Franklin Biotechnology Discv A(acc)USD1.84371.6234178729400
2024-09-30iShares Russell 2000 ETF1.32870.0269128802600
2024-08-31Fidelity Select Biotechnology1.11710.2806108295600
2024-09-30Franklin Biotechnology Discovery A1.0531.6005102078900
2024-09-30SPDR® S&P Biotech ETF0.94390.176915071-21371-2.2821
2024-03-31MEDICAL BioHealth EUR Acc0.88711.0791859966468788119.8401
2024-08-31Vanguard Institutional Extnd Mkt Idx Tr0.83810.009881247712970.1599
2024-07-31Fidelity Small Cap Index0.53740.019952094725881298.7323
2024-09-30iShares Russell 2000 Growth ETF0.45320.052843938500
2024-08-31APO Medical Opportunities R0.44150.666842800900
2024-09-30Invesco Dorsey Wright SmallCap Momt ETF0.40970.586439719600
2024-09-30iShares Biotechnology ETF0.36720.06813559816840.1925
2024-09-30State St Russell Sm/Mid Cp® Indx NL Cl C0.33120.0132108600
2024-08-31Fidelity Extended Market Index0.32210.009731220486052.8343
2024-09-30Royce Smaller-Companies Growth Svc0.28572.174627700020000.7273
2024-09-28Schwab US Small-Cap ETF™0.25850.019825054700
2024-09-30Royce Micro-Cap Invmt0.20950.965720312400
2024-08-31Vanguard Russell 2000 ETF0.20650.023820013769213.582
2024-09-30State St Russell Sm Cap® Indx SL Cl I0.19630.027819030000
Total 13.95249.423113525721+727955+5.4%

5.3. Insider Transactions

Insiders are holding 23.214% of the shares of Silverback Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-16Kathleen D ScottSELL1250016
2024-10-15Sarina TanimotoSELL10000014.88
2024-10-08Richard E LowenthalSELL10000013.83
2024-09-18Eric KarasSELL1000014
2024-09-17Richard E LowenthalSELL10000012.93
2024-08-26Peter A ThompsonSELL8369513
2024-08-23Peter A ThompsonSELL6950013.03
2024-08-21Peter A ThompsonSELL40770013.56
2024-08-20Brian DorseySELL5000015
2024-08-20Kathleen D ScottSELL1250016
2024-08-20Richard E LowenthalSELL10000015.03
2024-08-19Eric KarasSELL1000014
2024-07-16Richard E LowenthalSELL10000011.4
2024-07-09Sarina TanimotoSELL1000009.62
2024-06-12Sarina TanimotoSELL958629.15
2024-06-11Richard E LowenthalSELL41389
2024-05-16Sarina TanimotoSELL890969.06
2024-05-15Richard E LowenthalSELL51479.05
2024-05-14Sarina TanimotoSELL57579.01
2024-05-07Sarina TanimotoSELL1000009.34
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Gross Profit  -7,2987,277-21-21-4231-11493482



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets221,966
Total Liabilities6,725
Total Stockholder Equity215,241
 As reported
Total Liabilities 6,725
Total Stockholder Equity+ 215,241
Total Assets = 221,966

Assets

Total Assets221,966
Total Current Assets220,437
Long-term Assets1,529
Total Current Assets
Cash And Cash Equivalents 36,626
Short-term Investments 182,118
Net Receivables 564
Other Current Assets 1,129
Total Current Assets  (as reported)220,437
Total Current Assets  (calculated)220,437
+/-0
Long-term Assets
Property Plant Equipment 782
Intangible Assets 446
Long-term Assets Other 301
Long-term Assets  (as reported)1,529
Long-term Assets  (calculated)1,529
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,725
Long-term Liabilities0
Total Stockholder Equity215,241
Total Current Liabilities
Short-term Debt 160
Accounts payable 3,272
Other Current Liabilities 3,280
Total Current Liabilities  (as reported)6,725
Total Current Liabilities  (calculated)6,712
+/- 13
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock10
Retained Earnings -154,111
Accumulated Other Comprehensive Income -145
Other Stockholders Equity 369,487
Total Stockholder Equity (as reported)215,241
Total Stockholder Equity (calculated)215,241
+/-0
Other
Capital Stock10
Cash and Short Term Investments 218,744
Common Stock Shares Outstanding 96,828
Current Deferred Revenue13
Liabilities and Stockholders Equity 221,966
Net Debt -36,466
Net Invested Capital 215,241
Net Working Capital 214,013
Property Plant and Equipment Gross 932
Short Long Term Debt Total 160



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
0
61,446
0
46,049
271,064
281,435
271,192
258,752
248,556
233,188
227,583
221,966
221,966227,583233,188248,556258,752271,192281,435271,06446,049061,4460
   > Total Current Assets 
60,730
60,730
45,388
45,388
270,799
277,700
267,350
255,034
244,466
231,563
226,008
220,437
220,437226,008231,563244,466255,034267,350277,700270,79945,38845,38860,73060,730
       Cash And Cash Equivalents 
0
60,063
0
44,590
203,224
210,518
87,862
119,017
60,532
70,971
56,006
36,626
36,62656,00670,97160,532119,01787,862210,518203,22444,590060,0630
       Short-term Investments 
0
0
0
39,285
63,400
63,863
176,687
133,191
181,370
157,389
167,626
182,118
182,118167,626157,389181,370133,191176,68763,86363,40039,285000
       Net Receivables 
1
1
35
35
395
1,009
522
962
814
795
685
564
5646857958149625221,009395353511
       Other Current Assets 
0
666
0
763
4,175
3,319
2,801
2,826
2,564
2,408
1,691
1,129
1,1291,6912,4082,5642,8262,8013,3194,17576306660
   > Long-term Assets 
0
716
0
661
265
3,735
3,842
3,718
4,090
1,625
1,575
1,529
1,5291,5751,6254,0903,7183,8423,73526566107160
       Property Plant Equipment 
693
693
638
638
15
774
982
943
917
824
814
782
78281482491794398277415638638693693
       Intangible Assets 
0
0
0
0
0
0
0
138
690
617
528
446
4465286176901380000000
       Long-term Assets Other 
0
23
0
-24,195
-250
2,961
2,860
2,637
2,483
184
233
301
3012331842,4832,6372,8602,961-250-24,1950230
> Total Liabilities 
0
92,715
0
90,081
3,990
8,549
10,037
10,200
11,272
2,428
3,715
6,725
6,7253,7152,42811,27210,20010,0378,5493,99090,081092,7150
   > Total Current Liabilities 
8,187
8,187
7,461
7,461
3,990
5,444
9,838
10,054
11,180
2,391
3,715
6,725
6,7253,7152,39111,18010,0549,8385,4443,9907,4617,4618,1878,187
       Short-term Debt 
0
3,623
0
3,732
215
230
232
233
235
237
217
160
1602172372352332322302153,73203,6230
       Short Long Term Debt 
0
3,479
0
3,505
0
0
0
0
0
0
0
0
000000003,50503,4790
       Accounts payable 
1,786
1,786
1,937
1,937
126
1,659
2,580
9,651
2,966
759
839
3,272
3,2728397592,9669,6512,5801,6591261,9371,9371,7861,786
       Other Current Liabilities 
1,532
1,321
693
1,448
3,864
3,272
7,016
9,821
10,945
1,391
2,612
3,280
3,2802,6121,39110,9459,8217,0163,2723,8641,4486931,3211,532
   > Long-term Liabilities 
0
84,528
0
82,620
5,518
3,105
199
146
92
37
0
0
0037921461993,1055,51882,620084,5280
       Capital Lease Obligations Min Short Term Debt
0
-2,999
0
-3,156
-215
251
199
146
92
37
0
0
003792146199251-215-3,1560-2,9990
       Long-term Liabilities Other 
0
0
0
0
0
3,105
199
146
0
0
0
0
00001461993,10500000
> Total Stockholder Equity
0
-31,269
0
-44,032
267,074
272,886
261,155
248,552
237,284
230,760
223,868
215,241
215,241223,868230,760237,284248,552261,155272,886267,074-44,0320-31,2690
   Common Stock
257
257
260
260
4
9
9
9
9
10
10
10
10101099994260260257257
   Retained Earnings Total Equity0000-109,269-91,899-76,938-248,1360000
   Accumulated Other Comprehensive Income 
0
0
0
-1,548
-1,623
407
68
-180
-161
49
-124
-145
-145-12449-161-18068407-1,623-1,548000
   Capital Surplus 
0
0
0
0
516,829
349,408
352,977
357,992
0
0
0
0
0000357,992352,977349,408516,8290000
   Treasury Stock000000000000
   Other Stockholders Equity 
0
10,730
0
-62,857
440,790
349,408
81,785
99,240
113,015
128,816
365,577
369,487
369,487365,577128,816113,01599,24081,785349,408440,790-62,857010,7300



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue30
Cost of Revenue-73
Gross Profit-43-43
 
Operating Income (+$)
Gross Profit-43
Operating Expense-67,477
Operating Income-67,520-67,520
 
Operating Expense (+$)
Research Development20,266
Selling General Administrative47,284
Selling And Marketing Expenses-73
Operating Expense67,47767,477
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-67,520
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-54,365-80,675
EBIT - interestExpense = -67,520
-54,460
-54,365
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-67,520-54,365
Earnings Before Interest and Taxes (EBITDA)-67,447
 
After tax Income (+$)
Income Before Tax-54,365
Tax Provision-0
Net Income From Continuing Ops-61,626-54,365
Net Income-54,365
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses67,550
Total Other Income/Expenses Net13,1550
 

Technical Analysis of Silverback Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Silverback Therapeutics Inc. The general trend of Silverback Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Silverback Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Silverback Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 17.08.

The bearish price targets are: 13.29 > 11.00 > 9.31.

Tweet this
Silverback Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Silverback Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Silverback Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Silverback Therapeutics Inc. The current macd is 0.28050836.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Silverback Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Silverback Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Silverback Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Silverback Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSilverback Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Silverback Therapeutics Inc. The current adx is 15.98.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Silverback Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Silverback Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Silverback Therapeutics Inc. The current sar is 16.52.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Silverback Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Silverback Therapeutics Inc. The current rsi is 53.60. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Silverback Therapeutics Inc Daily Relative Strength Index (RSI) ChartSilverback Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Silverback Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Silverback Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Silverback Therapeutics Inc Daily Stochastic Oscillator ChartSilverback Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Silverback Therapeutics Inc. The current cci is -7.03082625.

Silverback Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSilverback Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Silverback Therapeutics Inc. The current cmo is 4.58376737.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Silverback Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSilverback Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Silverback Therapeutics Inc. The current willr is -61.0738255.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Silverback Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Silverback Therapeutics Inc Daily Williams %R ChartSilverback Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Silverback Therapeutics Inc.

Silverback Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Silverback Therapeutics Inc. The current atr is 0.88517645.

Silverback Therapeutics Inc Daily Average True Range (ATR) ChartSilverback Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Silverback Therapeutics Inc. The current obv is 86,678,929.

Silverback Therapeutics Inc Daily On-Balance Volume (OBV) ChartSilverback Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Silverback Therapeutics Inc. The current mfi is 56.74.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Silverback Therapeutics Inc Daily Money Flow Index (MFI) ChartSilverback Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Silverback Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Silverback Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Silverback Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.604
Ma 20Greater thanMa 5015.132
Ma 50Greater thanMa 10014.050
Ma 100Greater thanMa 20012.206
OpenGreater thanClose14.840
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Silverback Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Silverback Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Silverback Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Silverback Therapeutics Inc

I send you an email if I find something interesting about Silverback Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Silverback Therapeutics Inc.

Receive notifications about Silverback Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.